Overview
Listed as the lecanemab sponsor partner on this atlas. Company pages here are map nodes, not investment advice.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +6
Lecanemab is an infused antibody for early Alzheimer’s disease after amyloid is confirmed. It can cause brain swelling or bleeding on MRI and is not a cure.
Similar pages
not linked directly; found by shared links- Key paperLecanemab in Early Alzheimer’s Disease (CLARITY AD)
Shares CLARITY AD, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- CompanyBiogen
Shares CLARITY AD, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyApoE testing
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyAnti-amyloid antibodies
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TermARIA
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- PairingLecanemab with MRI monitoring
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- IdeaAntibody trials that enrol mixed and comorbid disease
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TargetAmyloid-beta
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.